English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, May 20, 2021
冠科美博上海分公司正式開業
APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH
Tuesday, March 9, 2021
APOLLOMICS(冠科美博)任命K. PEONY YU余健鸿医学博士为首席医学官(CMO)
APOLLOMICS(冠科美博)任命K. PEONY YU余健鴻醫學博士為首席醫學官(CMO)
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
Thursday, March 4, 2021
APOLLOMICS(冠科美博)UPROLESELAN注射液(APL-106)中国I期临床试验第一例受试者成功入组
APOLLOMICS(冠科美博)UPROLESELAN注射液(APL-106)中國I期臨床試驗第一例受試者成功入組
APOLLOMICS, INC ANNOUNCES SUCCESSFUL ENROLLMENT OF FIRST PATIENT INTO PHASE 1 CLINICAL TRIAL OF APL-106 (UPROLESELAN INJECTION) IN CHINA
Friday, February 12, 2021
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
APOLLOMICS(冠科美博)在中國和南非引進一款靶向主動免疫檢查點控制劑重組疫苗

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575